Welcome to our dedicated page for Inogen news (Ticker: INGN), a resource for investors and traders seeking the latest updates and insights on Inogen stock.
Inogen reports recurring developments as a respiratory medical technology company serving homecare patients with chronic respiratory conditions. Its updates focus on financial results and outlook, portable oxygen concentrators, Simeox airway clearance, stationary oxygen concentrators, and Aurora CPAP masks for obstructive sleep apnea.
Company news also covers product introductions, clinical evidence and reimbursement work, international market activity, commercial partnerships, leadership and board changes, inducement equity awards, share repurchase actions, and investor conference participation.
Inogen, Inc. (NASDAQ: INGN) has appointed Dr. Stanislav Glezer as Executive Vice President and Chief Medical Officer, effective June 21, 2021. CEO Nabil Shabshab expressed confidence that Dr. Glezer's over 25 years of experience in clinical research and medical affairs will enhance Inogen's clinical capabilities and market development efforts. Dr. Glezer aims to lead Medical Affairs, Clinical Research, and Regulatory organizations to improve patient outcomes through clinical evidence collaboration. His previous roles include significant positions at Becton, Dickinson and Company, and Novo Nordisk.
Inogen, a medical technology company, has appointed Elizabeth (Beth) Mora to its Board of Directors, effective May 24, 2021. Mora, a seasoned executive with extensive financial expertise, fills the vacancy left by R. Scott Greer, who resigned from the board. She will also serve on the Audit Committee. CEO Nabil Shabshab expressed confidence in Mora's ability to enhance strategic initiatives aimed at increasing patient access to oxygen therapy products. The board transition aims to strengthen governance and support Inogen's growth objectives, scheduled for review at the 2024 annual meeting.
Inogen, Inc. (NASDAQ: INGN), a leader in respiratory health technologies, will present at the 41st Annual William Blair Virtual Growth Stock Conference on June 3rd, 2021, at 4:00 p.m. CDT. CEO Nabil Shabshab and CFO Alison Bauerlein will lead the presentation, which can be accessed via the company's Investor Relations page. This presentation highlights Inogen's commitment to innovation in portable oxygen concentrators, enhancing care options for patients with chronic respiratory conditions.
Inogen, Inc. (NASDAQ: INGN) reported Q1 2021 revenue of $86.9 million, a 1.8% decline from Q1 2020, largely due to COVID-19 impacts. Domestic business-to-business revenue rose 11.6% to $30.7 million, while rental revenue surged 84.2% to $9.9 million. As of March 31, 2021, cash and equivalents totaled $233.2 million, with no debt. Operating loss was $2.1 million, and net loss was $0.7 million. The company refrained from providing full-year guidance for 2021 due to pandemic uncertainties, while anticipating increased operational expenses as it invests in growth initiatives.
Inogen, a medical technology company focused on respiratory products, will announce its first quarter 2021 financial results on May 4, 2021, after market close. A conference call will follow at 1:30 PM PT/4:30 PM ET, with a replay available until May 18, 2021. Investors can listen live via phone or through Inogen's Investor Relations website. The company specializes in portable oxygen concentrators for patients with chronic respiratory conditions.
Inogen, Inc. (NASDAQ: INGN) announced the appointment of George Parr as Executive Vice President and Chief Commercial Officer, effective April 12, 2021. This follows the planned departure of Byron Myers and Arron Retterer, effective June 4, 2021. Inogen expects first-quarter 2021 revenue to range from $84.0 million to $87.0 million, based on preliminary estimates. Parr brings over 25 years of experience in the medical technology sector, which the company hopes will enhance growth and patient access to its products. The leadership changes aim to strengthen Inogen’s market position.
Inogen, a medical technology company known for innovative respiratory products, will present at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021. President and CEO Nabil Shabshab and CFO Alison Bauerlein will host the presentation at 10:15 a.m. ET. Interested parties can access the webcast on Inogen's Investor Relations website, with a replay available for 90 days following the event. Inogen specializes in portable oxygen concentrators designed for long-term supplemental oxygen therapy in homecare settings.
Inogen, Inc. (NASDAQ: INGN), a medical technology company, announced its participation in the KeyBanc Life Sciences & MedTech Investor Forum. The presentation is scheduled for March 23, 2021, at 3:30 p.m. ET, featuring President and CEO Nabil Shabshab, and CFO Alison Bauerlein. Interested individuals can access the webcast on Inogen's Investor Relations page. The company emphasizes transparency by utilizing its website to disclose non-public material information in compliance with Regulation FD. Inogen develops innovative portable oxygen concentrators for patients with chronic respiratory conditions.
Inogen, a medical technology company, reported Q4 2020 revenue of $74 million, down 6.3% year-over-year, primarily impacted by COVID-19. Domestic B2B sales rose 17.9% to $24.2 million, while rental revenue surged 71.7% to $9.4 million. The company incurred a net loss of $5.1 million and had cash reserves of $231.2 million with no debt. For 2021, Inogen refrained from providing financial guidance due to market uncertainties but anticipates improvements in domestic sales and rental revenue despite expected declines in international and direct-to-consumer sales.
Inogen, Inc. (NASDAQ: INGN) announced the appointment of Kristen Miranda to its Board of Directors, effective March 1, 2021, filling the vacancy left by Scott Beardsley’s resignation. Miranda brings extensive healthcare experience, having served as Aetna’s West Region President since 2017. Her addition aims to enhance payor acceptance of Inogen’s products. CEO Nabil Shabshab emphasized her healthcare background as a key asset for expanding patient access and enhancing shareholder value. The company continues to focus on innovative respiratory solutions for homecare settings.